A detailed history of Price T Rowe Associates Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 819,296 shares of PTGX stock, worth $28.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
819,296
Previous 823,740 0.54%
Holding current value
$28.3 Million
Previous $18.9 Million 25.49%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$21.79 - $32.15 $96,834 - $142,874
-4,444 Reduced 0.54%
819,296 $23.7 Million
Q4 2023

Feb 14, 2024

SELL
$14.05 - $23.44 $115,954 - $193,450
-8,253 Reduced 0.99%
823,740 $18.9 Million
Q3 2023

Nov 14, 2023

BUY
$16.68 - $23.66 $5,004 - $7,098
300 Added 0.04%
831,993 $13.9 Million
Q2 2023

Aug 14, 2023

BUY
$18.02 - $29.36 $7.5 Million - $12.2 Million
416,419 Added 100.28%
831,693 $23 Million
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $4.48 Million - $10.5 Million
415,274 New
415,274 $9.55 Million
Q2 2022

Aug 15, 2022

SELL
$7.06 - $25.52 $2.12 Million - $7.67 Million
-300,468 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$23.34 - $36.08 $1.79 Million - $2.77 Million
-76,664 Reduced 20.33%
300,468 $7.12 Million
Q4 2021

Feb 14, 2022

SELL
$17.63 - $37.1 $2.02 Million - $4.25 Million
-114,509 Reduced 23.29%
377,132 $12.9 Million
Q3 2021

Nov 15, 2021

SELL
$12.95 - $49.69 $6.41 Million - $24.6 Million
-494,613 Reduced 50.15%
491,641 $8.71 Million
Q2 2021

Aug 16, 2021

BUY
$25.57 - $44.88 $1.86 Million - $3.26 Million
72,664 Added 7.95%
986,254 $44.3 Million
Q1 2021

May 17, 2021

BUY
$19.02 - $31.15 $1.3 Million - $2.12 Million
68,195 Added 8.07%
913,590 $23.7 Million
Q4 2020

Feb 16, 2021

BUY
$18.49 - $25.13 $15.6 Million - $21.2 Million
845,395 New
845,395 $17 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.69B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.